SEC Filing Summary: AspenBio Pharma, Inc. (10-Q)
Business Context and Reporting Period
This is a Quarterly Report on Form 10-Q for AspenBio Pharma, Inc., covering the period ended September 30, 2009. The company is a biopharmaceutical firm focused on developing diagnostic tests (specifically the AppyScore appendicitis test) and animal health products (BoviPure LH and FSH). The registrant is classified as an accelerated filer and is not a shell company.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2009 | Nine Months Ended Sep 30, 2009 | Nine Months Ended Sep 30, 2008 |
|---|---|---|---|
| Sales | $69,212 | $222,251 | $702,959 |
| Gross Profit (Loss) | $52,566 | $(81,284) | $206,020 |
| Operating Loss | $(3,808,864) | $(10,394,854) | $(7,607,033) |
| Net Loss | $(3,830,389) | $(10,330,592) | $(7,123,254) |
| Net Loss Per Share (Basic/Diluted) | $(0.12) | $(0.32) | $(0.23) |
| Cash and Cash Equivalents | $7,643,571 (as of Sep 30, 2009) | ||
| Short-term Investments | $1,808,528 (as of Sep 30, 2009) | ||
| Total Debt (Notes Payable) | $2,829,963 (as of Sep 30, 2009) | ||
| Working Capital | $7,245,332 (as of Sep 30, 2009) |
Material Changes vs. Prior Period
- Revenue Decline: Sales for the nine months ended September 30, 2009, decreased by 68% ($481,000) compared to the prior year period. This is attributed to general economic conditions, timing of customer orders, and product mix changes.
- Gross Margin Shift: The company reported a gross loss of 37% of sales for the nine-month 2009 period, compared to a 29% gross margin in 2008. This was driven by lower sales volume against fixed overhead costs.
- Expense Increases:
- Selling, General, and Administrative (SG&A): Increased 26% ($907,000) year-over-year, primarily due to hiring additional personnel ($1.05M) to support development and licensing activities, partially offset by reduced public company expenses.
- Research and Development (R&D): Increased 37% ($1.6M) year-over-year, driven by clinical trials and FDA submission activities for the AppyScore product.
- Interest Income: Decreased significantly from $634,000 in 2008 to $171,000 in 2009 due to lower cash balances and reduced investment returns.
Outlook, Risks, and Unusual Items
- Liquidity and Capital Resources: The company reported a net loss of $10.3 million for the nine-month period. However, working capital remains positive at approximately $7.2 million. Management believes current resources are sufficient for near-term operations.
- Subsequent Event (Financing): In October 2009, subsequent to the reporting period, the company completed a public offering of 5,155,000 shares, generating approximately $8.3 million in net proceeds to fund product development and working capital.
- Key Agreements:
- Novartis: A license agreement for bovine products includes deferred revenue. $48,000 was recognized in the nine-month 2009 period.
- Merial: A dispute exists regarding a bovine diagnostic blood test agreement; Merial notified the company of unmet development goals, requiring a $100,000 payment or execution of a first right of refusal. No determination had been made as of September 30, 2009.
- Risks: The company expects to continue incurring losses. Success depends on FDA clearance for the AppyScore test and commercialization of bovine products. Failure to achieve these milestones could impair assets and necessitate reliance on other revenue sources.
Investor Verification Checklist
- Capital Raise Status: Verify the closing and use of proceeds from the October 2009 public offering mentioned in subsequent events.
- Merial Dispute Resolution: Monitor the outcome of the $100,000 payment/first right of refusal decision regarding the Merial agreement.
- FDA Progress: Track the status of the Premarket Notification [510(k)] submission for the AppyScore appendicitis test.
- Burn Rate: Assess the sustainability of the current cash position given the $10.3M net loss and ongoing R&D expenditures.
- Stock-Based Compensation: Review the impact of $1.2M in non-cash stock-based compensation on future cash flow projections.